BOLT Investors Have Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit

Core Points - A class action lawsuit has been filed against Bolt Biotherapeutics, Inc. for misleading statements regarding its product BDC-1001, which is designed to target HER2 in certain cancers [7][8] - The lead plaintiff deadline for the class action is September 3, 2024, and investors who purchased Bolt securities during the Class Period (February 5, 2021 to May 14, 2024) may be entitled to compensation [7][8] Summary by Category Class Action Details - Investors can join the class action without any out-of-pocket fees through a contingency fee arrangement [3] - No class has been certified yet, meaning investors are not represented by counsel unless they retain one [2] Allegations Against the Company - The lawsuit claims that Bolt overstated the effectiveness of BDC-1001 and its product pipeline, which could lead to significant operational risks [8] - The company allegedly failed to disclose that BDC-1001 was unlikely to meet its success criteria, impacting its commercial prospects [8]